TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35063186

Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation (DBS) with personalized stimulation parameters based on intracranial recordings
Number of subjects: 1

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 1
Study: 33676560

Group type: COMPARATOR
Intervention: Standard routine care
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: Behavioural nudges (text messages) along with the use of a social media platform
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: Midwife-led continuity care involving individualised teleconferencing sessions
Number of subjects: 750
Study: 33040465

Group type: EXPERIMENTAL
Intervention: TDF/FTC plus vitamin D3 and calcium supplementation (400 units of vitamin D3 and 1200 mg of elemental calcium/day)
Number of subjects: 100

Group type: COMPARATOR
Intervention: TDF/FTC only
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: TDF/FTC plus vitamin D3 and calcium supplementation
Number of subjects: 100
Study: 35950283

Group type: EXPERIMENTAL
Intervention: Transradial access (TRA) with patients in foot‐first position (Group A)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Transradial access (TRA) with patients in conventional head‐first position (Group B)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Transradial access (TRA) with patients in conventional head‐first position via right radial artery (Group C)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Transfemoral access (TFA) with patients in conventional head‐first position (Group D)
Number of subjects: 120
Study: 34979630

Group type: EXPERIMENTAL
Intervention: FKScope®
Number of subjects: 64

Group type: COMPARATOR
Intervention: Macintosh
Number of subjects: 64
Study: 33009060

Group type: EXPERIMENTAL
Intervention: Dilation
Number of subjects: 102

Group type: COMPARATOR
Intervention: No Dilation
Number of subjects: 102
Study: 34021020

Group type: EXPERIMENTAL
Intervention: GAD-alum therapy with vitamin D supplementation (4 μg GAD-alum intralymphatic injections, 2,000 IE vitamin D daily for 120 days)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: GAD-alum therapy with vitamin D supplementation in HLA DR3-DQ2 genotype (n = 29)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Placebo (n = 17)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: GAD-alum therapy with vitamin D supplementation
Number of subjects: 109
Study: 36244918

Group type: EXPERIMENTAL
Intervention: Ambient Intelligence monitoring of caregiver activity
Number of subjects: 14
Study: 32212866

Group type: EXPERIMENTAL
Intervention: Ceftolozane-tazobactam
Number of subjects: 0
Study: 35490470

Group type: EXPERIMENTAL
Intervention: Nomogram model based on gender, age, baseline NIHSS score, hyperhomocysteinemia (HHcy), and multiple lesions
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Nomogram model
Number of subjects: 191
Study: 35283526

Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg once daily for 6 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rupatadine 10 mg once daily for 6 weeks
Number of subjects: 0
Study: 32709912

Group type: EXPERIMENTAL
Intervention: 12-week exercise programme
Number of subjects: 22

Group type: COMPARATOR
Intervention: Treatment as usual (control)
Number of subjects: 22
Study: 34876454

Group type: EXPERIMENTAL
Intervention: TNF receptor‐1
Number of subjects: 2553

Group type: EXPERIMENTAL
Intervention: TNF receptor‐2
Number of subjects: 2553

Group type: EXPERIMENTAL
Intervention: Highest quartile of TNF receptor‐1 (≥2992 ng/ml)
Number of subjects: 2553

Group type: EXPERIMENTAL
Intervention: Highest quartile of TNF receptor‐2 (≥11,394 ng/ml)
Number of subjects: 2553

Group type: COMPARATOR
Intervention: Lower three quartiles of TNF receptor‐1
Number of subjects: 2553

Group type: COMPARATOR
Intervention: Lower three quartiles of TNF receptor‐2
Number of subjects: 2553
Study: 33978597

Group type: EXPERIMENTAL
Intervention: PEARS intervention with low glycemic index dietary intervention and exercise prescription
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Smartphone app support
Number of subjects: 149
Study: 32856448

Group type: EXPERIMENTAL
Intervention: Topical TXA (3 g in 50 ml of saline solution)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Intravenous + topical TXA (3 g topical + 2 g in 100 ml of saline solution intravenously)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 75
Study: 33678097

Group type: EXPERIMENTAL
Intervention: CinnoVex®
Number of subjects: 41

Group type: COMPARATOR
Intervention: Avonex®
Number of subjects: 41
Study: 34098559

Group type: EXPERIMENTAL
Intervention: Tenapanor
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 35922460

Group type: EXPERIMENTAL
Intervention: Variable MTV
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fixed control MTV
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unsupervised control MTV
Number of subjects: 0
Study: 35790696

Group type: EXPERIMENTAL
Intervention: Intravenous ferric derisomaltose (FDI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saccharated ferric oxide (SFO)
Number of subjects: 0
Study: 33941146

Group type: EXPERIMENTAL
Intervention: Simplified Accelerated Recovery Protocol (SARP)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Conventional postoperative care (CC)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: SARP (tolerated)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: SARP (not tolerated)
Number of subjects: 161
Study: 36126411

Group type: EXPERIMENTAL
Intervention: SCT630
Number of subjects: 367

Group type: COMPARATOR
Intervention: adalimumab
Number of subjects: 367
Study: 32789929

Group type: EXPERIMENTAL
Intervention: Care for Participation+ (CFP+) intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Participation Mind Map control group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 0
Study: 32634486

Group type: EXPERIMENTAL
Intervention: Team Clinic care model
Number of subjects: 0
Study: 35798491

Group type: EXPERIMENTAL
Intervention: Femoral Approach
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Radial Approach
Number of subjects: 0
Study: 34591079

Group type: EXPERIMENTAL
Intervention: TAC 10 mg/mL, 24 hours before surgery
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: TAC 10 mg/mL, 1 hour before surgery
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: TAC 40 mg/mL, 24 hours before surgery
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: TAC 40 mg/mL, 1 hour before surgery
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Patients with thickening of the middle ear
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Overall TAC levels in perilymph
Number of subjects: 40
Study: 35869315

Group type: EXPERIMENTAL
Intervention: Self-compression
Number of subjects: 495

Group type: COMPARATOR
Intervention: Radiographer-led compression
Number of subjects: 495
Study: 32739562

Group type: EXPERIMENTAL
Intervention: Health Information Preferences (HIPs) regarding diagnosis and treatment details
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Health Information Preferences (HIPs) regarding likely outcome of disease
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Curability beliefs regarding cancer prognosis
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Prognostic understanding and its association with HIPs
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Prognostic understanding and its association with religiosity and quality of life
Number of subjects: 206
Study: 34547529

Group type: EXPERIMENTAL
Intervention: 2 mg aflibercept every 16 weeks (2Q16)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2 mg aflibercept every 8 weeks as needed (2Q8PRN)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept injections
Number of subjects: 0
Study: 33235104

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 5 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 40 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 34534493

Group type: EXPERIMENTAL
Intervention: Sodium thiosulfate (STS) 12.5 grams intravenously
Number of subjects: 380

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Sodium thiosulfate (STS)
Number of subjects: 380
Study: 32434978

Group type: EXPERIMENTAL
Intervention: Short-fiber-reinforced resin composite (SFRC)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Chairside indirect restorations (Grandioso inlay system)
Number of subjects: 76
Study: 33181046

Group type: EXPERIMENTAL
Intervention: ALIGN intervention (Assessing & Listening to Individual Goals and Needs)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: ALIGN intervention
Number of subjects: 120
Study: 33510892

Group type: EXPERIMENTAL
Intervention: 750 mg Curcuma longa
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: 1500 mg Curcuma longa
Number of subjects: 78

Group type: COMPARATOR
Intervention: Simethicone
Number of subjects: 78
Study: 34008052

Group type: EXPERIMENTAL
Intervention: Once-daily inhaled budesonide
Number of subjects: 80

Group type: COMPARATOR
Intervention: Twice-daily inhaled budesonide
Number of subjects: 80
Study: 34753452

Group type: EXPERIMENTAL
Intervention: Capecitabine (Cape) + Oxaliplatin (Oxa)
Number of subjects: 4307

Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil (5-FU) + Oxaliplatin (Oxa)
Number of subjects: 4307

Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 4307

Group type: COMPARATOR
Intervention: Anastrozole
Number of subjects: 4307
Study: 32448136

Group type: EXPERIMENTAL
Intervention: CareDose 4D low-dose CT combined with Karl 3D technology
Number of subjects: 60

Group type: COMPARATOR
Intervention: Regular CT (control group)
Number of subjects: 60
Study: 34279646

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate therapy (40-75 mg/kg)
Number of subjects: 816

Group type: COMPARATOR
Intervention: 5.5% saline placebo
Number of subjects: 816

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium therapy (2011-2016)
Number of subjects: 816

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium therapy (2017-2019)
Number of subjects: 816

Group type: EXPERIMENTAL
Intervention: Additional albuterol use
Number of subjects: 816

Group type: EXPERIMENTAL
Intervention: Increase in PRAM score at disposition (per 1-U increase)
Number of subjects: 816

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium therapy in children with a disposition PRAM score of 3 or lower
Number of subjects: 816
Study: 32189664

Group type: EXPERIMENTAL
Intervention: 40 HBOTs at 150 kPa/60 minutes, once daily, 5 days per week for 8 weeks
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control Group (no treatment)
Number of subjects: 63
Study: 35419791

Group type: EXPERIMENTAL
Intervention: Motor imagery focused pelvic floor exercise (MOPEXE)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Micronized purified flavanoid fraction (MPFF)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Acupressure
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Naproxen sodium (NS)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 85
Study: 33779016

Group type: EXPERIMENTAL
Intervention: Presence of tobacco advertising banners
Number of subjects: 1099

Group type: COMPARATOR
Intervention: Proximity to schools
Number of subjects: 1099

Group type: COMPARATOR
Intervention: Other exposure measures (physical decay, presence of mosques, churches)
Number of subjects: 1099
Study: 35404135

Group type: EXPERIMENTAL
Intervention: Stapled anastomosis
Number of subjects: 90

Group type: COMPARATOR
Intervention: Hand-sewn anastomosis
Number of subjects: 90
Study: 34294923

Group type: EXPERIMENTAL
Intervention: SYNB1618 (engineered E. coli Nissle 1917)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 32109425

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Gefapixant 7.5 mg
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Gefapixant 20 mg
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Gefapixant 50 mg
Number of subjects: 253
Study: 35679950

Group type: EXPERIMENTAL
Intervention: Vonoprazan triple therapy (20 mg vonoprazan twice daily; 1 g amoxicillin 3 times daily)
Number of subjects: 1046

Group type: EXPERIMENTAL
Intervention: Vonoprazan dual therapy (20 mg vonoprazan twice daily; 1 g amoxicillin 3 times daily)
Number of subjects: 1046

Group type: COMPARATOR
Intervention: Lansoprazole triple therapy (30 mg lansoprazole; 1 g amoxicillin; 500 mg clarithromycin)
Number of subjects: 1046

Group type: EXPERIMENTAL
Intervention: Vonoprazan triple therapy
Number of subjects: 1046

Group type: EXPERIMENTAL
Intervention: Vonoprazan dual therapy
Number of subjects: 1046

Group type: COMPARATOR
Intervention: Lansoprazole triple therapy
Number of subjects: 1046
Study: 35750038

Group type: EXPERIMENTAL
Intervention: Atezolizumab 840 mg every 2 weeks with nab-paclitaxel and anthracycline-based chemotherapy
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo with nab-paclitaxel and anthracycline-based chemotherapy
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Atezolizumab 840 mg every 2 weeks with nab-paclitaxel and anthracycline-based chemotherapy (PD-L1-positive population)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo with nab-paclitaxel and anthracycline-based chemotherapy (PD-L1-positive population)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Atezolizumab 840 mg every 2 weeks
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 32436733

Group type: EXPERIMENTAL
Intervention: Etonogestrel implant
Number of subjects: 140

Group type: COMPARATOR
Intervention: Short-acting reversible contraception (SARC)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Non-hormonal contraception
Number of subjects: 140
Study: 35729713

Group type: EXPERIMENTAL
Intervention: Ozoralizumab plus MTX
Number of subjects: 381
Study: 33825274

Group type: EXPERIMENTAL
Intervention: Anti-fungal prophylaxis for intermediate risk patients (score 5-8)
Number of subjects: 1053

Group type: EXPERIMENTAL
Intervention: Anti-fungal prophylaxis for high risk patients (score >8)
Number of subjects: 1053

Group type: EXPERIMENTAL
Intervention: Anti-fungal prophylaxis for low risk patients (score 0-4)
Number of subjects: 1053
Study: 32977404

Group type: EXPERIMENTAL
Intervention: Curcumin (160 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fish oil (2000 mg DHA + 400 mg EPA/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of curcumin and fish oil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 36445151

Group type: EXPERIMENTAL
Intervention: TECAS (Transcutaneous electrical cranial-auricular acupoint stimulation)
Number of subjects: 468

Group type: COMPARATOR
Intervention: escitalopram
Number of subjects: 468
Study: 33473019

Group type: EXPERIMENTAL
Intervention: Nonsteroidal anti-inflammatory drug (NSAID)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: NSAID and antihistaminic drug combination
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Placebo drug
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Intracanal cryotherapy
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 94
Study: 32609523

Group type: EXPERIMENTAL
Intervention: Resistive Vibration Exercise (RVE)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: NEX (RVE combined with whey protein supplementation and alkaline salt)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 8
Study: 34932885

Group type: EXPERIMENTAL
Intervention: WL+EX
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: WL+SL
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: WL+EX+SL
Number of subjects: 0
Study: 34173923

Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 37

Group type: COMPARATOR
Intervention: i-view™ video laryngoscope
Number of subjects: 37

Group type: COMPARATOR
Intervention: C-MAC® video laryngoscope
Number of subjects: 37
Study: 93178847

Group type: EXPERIMENTAL
Intervention: Interferon alfa therapy for 26 weeks
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Interferon alfa therapy
Number of subjects: 53
Study: 35968668

Group type: EXPERIMENTAL
Intervention: Vacuum-formed retainers (VFR) in the mandible (n=52)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Bonded cuspid-to-cuspid retainers (CTC) (n=52)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Both groups had a VFR in the maxilla
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Both groups (VFR and CTC)
Number of subjects: 104
Study: 36494045

Group type: EXPERIMENTAL
Intervention: Tai Chi intervention, remotely delivered, twice a week for 12 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wellness control condition, remotely delivered, twice a week for 12 weeks
Number of subjects: 0
Study: 33273302

Group type: EXPERIMENTAL
Intervention: LEDT at 630 nm (4.6 J·cm ‐2 , 97 J energy)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: LEDT at 940 nm (4.6 J·cm ‐2 , 114 J energy)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 32139212

Group type: EXPERIMENTAL
Intervention: RHB-102 (24-mg bimodal-release ondansetron)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147
Study: 32276609

Group type: EXPERIMENTAL
Intervention: Peak airway pressure at 30 cm H2O
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Peak airway pressure at 40 cm H2O
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Peak airway pressure at 50 cm H2O
Number of subjects: 134

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 134
Study: 36162818

Group type: EXPERIMENTAL
Intervention: Ground coffee (1-5 cups/day)
Number of subjects: 449563

Group type: EXPERIMENTAL
Intervention: Instant coffee (2-3 cups/day)
Number of subjects: 449563

Group type: EXPERIMENTAL
Intervention: Decaffeinated coffee (2-3 cups/day)
Number of subjects: 449563

Group type: EXPERIMENTAL
Intervention: Ground coffee (2-3 cups/day)
Number of subjects: 449563
Study: 32215727

Group type: EXPERIMENTAL
Intervention: Drug plus psychotherapy (DPP) with olanzapine and metacognitive training (MCT) for 8 weeks
Number of subjects: 41

Group type: COMPARATOR
Intervention: Drug therapy (DT) with olanzapine for 8 weeks
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Drug plus psychotherapy (DPP) with olanzapine and MCT
Number of subjects: 41

Group type: COMPARATOR
Intervention: Drug therapy (DT) with olanzapine
Number of subjects: 41
Study: 32928184

Group type: EXPERIMENTAL
Intervention: Anxiety coping program (relaxation techniques, diaphragmatic breathing training, progressive muscle relaxation with light instrumental music)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Anxiety coping program
Number of subjects: 76
Study: 34304248

Group type: EXPERIMENTAL
Intervention: Combined DNA damage response (DDR) and BCL-2 inhibition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard chemotherapies
Number of subjects: 0
Study: 34034273

Group type: EXPERIMENTAL
Intervention: 2 L PEG + 290 µg linaclotide (2 L PEG + L group)
Number of subjects: 432

Group type: COMPARATOR
Intervention: 2 L PEG
Number of subjects: 432

Group type: COMPARATOR
Intervention: 4 L PEG
Number of subjects: 432
Study: 36366373

Group type: EXPERIMENTAL
Intervention: TURKOVAC
Number of subjects: 1290

Group type: COMPARATOR
Intervention: CoronaVac
Number of subjects: 1290
Study: 32633242

Group type: EXPERIMENTAL
Intervention: Mydrane (tropicamide 0.02%, phenylephrine 0.31%, lidocaine 1%)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Mydriatic drops (tropicamide 1% and phenylephrine 10%)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Mydrane and mydriatic drops (both groups)
Number of subjects: 64
Study: 35821033

Group type: EXPERIMENTAL
Intervention: Standard care + yoga (Study group, n = 121)
Number of subjects: 234

Group type: COMPARATOR
Intervention: Standard antenatal care (Control group, n = 113)
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Standard care + yoga (Study group)
Number of subjects: 234
Study: 33232470

Group type: EXPERIMENTAL
Intervention: Standardized exercise training
Number of subjects: 116
Study: 32915053

Group type: EXPERIMENTAL
Intervention: Finger feeding method (Group 1, n=35)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Syringe feeding method (Group 2, n=35)
Number of subjects: 70
Study: 35152908

Group type: EXPERIMENTAL
Intervention: M‐PHP combined with ipilimumab and nivolumab
Number of subjects: 88
Study: 34494129

Group type: EXPERIMENTAL
Intervention: Preoperative breast reconstruction information (Group A)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No preoperative breast reconstruction information (Group B)
Number of subjects: 100
Study: 35717284

Group type: EXPERIMENTAL
Intervention: Community navigator
Number of subjects: 40

Group type: COMPARATOR
Intervention: Self-navigation of community resources
Number of subjects: 40
Study: 35397159

Group type: EXPERIMENTAL
Intervention: IMT + WBV
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: IMTsham + WBV
Number of subjects: 42

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 42
Study: 33980234

Group type: EXPERIMENTAL
Intervention: Scaling and root planing (SRP) with metronidazole (MET) and oral hygiene instructions (OHI)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Scaling and root planing (SRP) + OHI
Number of subjects: 150

Group type: COMPARATOR
Intervention: Oral hygiene instructions (OHI) only
Number of subjects: 150
Study: 32195649

Group type: EXPERIMENTAL
Intervention: Iclaprim 80 mg
Number of subjects: 602

Group type: COMPARATOR
Intervention: Vancomycin 15 mg/kg administered intravenously every 12 hours for 5-14 days
Number of subjects: 602

Group type: EXPERIMENTAL
Intervention: Iclaprim
Number of subjects: 602

Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 602
Study: 36165726

Group type: EXPERIMENTAL
Intervention: Palbociclib plus cetuximab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo plus cetuximab
Number of subjects: 0
Study: 33369625

Group type: EXPERIMENTAL
Intervention: Motor Skill Training (MST)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Strength and Flexibility Exercise (SFE)
Number of subjects: 154